ARCHIVES

ODAC Recommends Approval Of Nplate For Thrombocytopenia.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

Leter: Payers Must Determine Appropriate Therapies

July 19, 1996

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

NCCS Networker Volume 3 Issue 4, Fall 1989

September 13, 1989

MGI Pharma, MethylGene Begin Phase II Trial Of MG98.

September 28, 2001

Also in this 8-page issue: The Cancer Letter wins two awards for its “authoritative examination” of NCI.

June 11, 2004

AACR Journal Publishes a Henschke Letter Without Disclosure of Conflicts.

April 25, 2008